Cargando…

Recent Developments in Microfluidic Technologies for Central Nervous System Targeted Studies

Neurodegenerative diseases (NDs) bear a lot of weight in public health. By studying the properties of the blood-brain barrier (BBB) and its fundamental interactions with the central nervous system (CNS), it is possible to improve the understanding of the pathological mechanisms behind these disorder...

Descripción completa

Detalles Bibliográficos
Autores principales: Teixeira, Maria Inês, Amaral, Maria Helena, Costa, Paulo C., Lopes, Carla M., Lamprou, Dimitrios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356280/
https://www.ncbi.nlm.nih.gov/pubmed/32545276
http://dx.doi.org/10.3390/pharmaceutics12060542
_version_ 1783558464205750272
author Teixeira, Maria Inês
Amaral, Maria Helena
Costa, Paulo C.
Lopes, Carla M.
Lamprou, Dimitrios A.
author_facet Teixeira, Maria Inês
Amaral, Maria Helena
Costa, Paulo C.
Lopes, Carla M.
Lamprou, Dimitrios A.
author_sort Teixeira, Maria Inês
collection PubMed
description Neurodegenerative diseases (NDs) bear a lot of weight in public health. By studying the properties of the blood-brain barrier (BBB) and its fundamental interactions with the central nervous system (CNS), it is possible to improve the understanding of the pathological mechanisms behind these disorders and create new and better strategies to improve bioavailability and therapeutic efficiency, such as nanocarriers. Microfluidics is an intersectional field with many applications. Microfluidic systems can be an invaluable tool to accurately simulate the BBB microenvironment, as well as develop, in a reproducible manner, drug delivery systems with well-defined physicochemical characteristics. This review provides an overview of the most recent advances on microfluidic devices for CNS-targeted studies. Firstly, the importance of the BBB will be addressed, and different experimental BBB models will be briefly discussed. Subsequently, microfluidic-integrated BBB models (BBB/brain-on-a-chip) are introduced and the state of the art reviewed, with special emphasis on their use to study NDs. Additionally, the microfluidic preparation of nanocarriers and other compounds for CNS delivery has been covered. The last section focuses on current challenges and future perspectives of microfluidic experimentation.
format Online
Article
Text
id pubmed-7356280
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73562802020-07-31 Recent Developments in Microfluidic Technologies for Central Nervous System Targeted Studies Teixeira, Maria Inês Amaral, Maria Helena Costa, Paulo C. Lopes, Carla M. Lamprou, Dimitrios A. Pharmaceutics Review Neurodegenerative diseases (NDs) bear a lot of weight in public health. By studying the properties of the blood-brain barrier (BBB) and its fundamental interactions with the central nervous system (CNS), it is possible to improve the understanding of the pathological mechanisms behind these disorders and create new and better strategies to improve bioavailability and therapeutic efficiency, such as nanocarriers. Microfluidics is an intersectional field with many applications. Microfluidic systems can be an invaluable tool to accurately simulate the BBB microenvironment, as well as develop, in a reproducible manner, drug delivery systems with well-defined physicochemical characteristics. This review provides an overview of the most recent advances on microfluidic devices for CNS-targeted studies. Firstly, the importance of the BBB will be addressed, and different experimental BBB models will be briefly discussed. Subsequently, microfluidic-integrated BBB models (BBB/brain-on-a-chip) are introduced and the state of the art reviewed, with special emphasis on their use to study NDs. Additionally, the microfluidic preparation of nanocarriers and other compounds for CNS delivery has been covered. The last section focuses on current challenges and future perspectives of microfluidic experimentation. MDPI 2020-06-11 /pmc/articles/PMC7356280/ /pubmed/32545276 http://dx.doi.org/10.3390/pharmaceutics12060542 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Teixeira, Maria Inês
Amaral, Maria Helena
Costa, Paulo C.
Lopes, Carla M.
Lamprou, Dimitrios A.
Recent Developments in Microfluidic Technologies for Central Nervous System Targeted Studies
title Recent Developments in Microfluidic Technologies for Central Nervous System Targeted Studies
title_full Recent Developments in Microfluidic Technologies for Central Nervous System Targeted Studies
title_fullStr Recent Developments in Microfluidic Technologies for Central Nervous System Targeted Studies
title_full_unstemmed Recent Developments in Microfluidic Technologies for Central Nervous System Targeted Studies
title_short Recent Developments in Microfluidic Technologies for Central Nervous System Targeted Studies
title_sort recent developments in microfluidic technologies for central nervous system targeted studies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356280/
https://www.ncbi.nlm.nih.gov/pubmed/32545276
http://dx.doi.org/10.3390/pharmaceutics12060542
work_keys_str_mv AT teixeiramariaines recentdevelopmentsinmicrofluidictechnologiesforcentralnervoussystemtargetedstudies
AT amaralmariahelena recentdevelopmentsinmicrofluidictechnologiesforcentralnervoussystemtargetedstudies
AT costapauloc recentdevelopmentsinmicrofluidictechnologiesforcentralnervoussystemtargetedstudies
AT lopescarlam recentdevelopmentsinmicrofluidictechnologiesforcentralnervoussystemtargetedstudies
AT lamproudimitriosa recentdevelopmentsinmicrofluidictechnologiesforcentralnervoussystemtargetedstudies